Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hippocampal volume in young adults with depression treated with mirtazapine vs mirtazapine + venlafaxine
2004-002788-25Phase 4Active
- Sponsor
- Friedrich-Alexander University Erlangen-Nuremberg
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in major depressive disorder (MDD) comparing Remergil monotherapy with Remergil + Trevilor retard combination therapy (2 arms). Primary endpoint: Categorical response to treatment. Started Jun 2006; status: active.
02
Drugs
mirtazapinevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-002788-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002788-25.